Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences, Oncothyreon, Keryx, Organovo

    Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences,
                         Oncothyreon, Keryx, Organovo

PR Newswire

CORAL SPRINGS, Florida, September 26, 2013

CORAL SPRINGS, Florida, September 26, 2013 /PRNewswire/ --

According to the Medical Market Forecastsissued by Espicom, the global
medical device, technology, and equipment market is expected to rise more than
$440.5 billion by 2018. issues market news updates for
today's active biotech companies: Alliqua, Inc. (OTCQB: ALQA), Pacific
Biosciences of California Inc. (NASDAQ: PACB), Oncothyreon Inc. (NASDAQ:
ONTY), Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) and Organovo Holdings,
Inc. (NYSE: ONVO).

Alliqua, Inc. (OTCQB: ALQA) Headline: Alliqua Becomes Exclusive Distributor
of Sorbion-Branded Wound Products in the Americas Through Agreement with
Carolon. Alliqua, Inc. today announced the Company has entered into an
agreement with Carolon Health Care Products through which it will gain both
new sales distribution pathways and established customers. As previously
announced, Alliqua has also entered into an agreement to become a sales and
distribution agent in the Americas for Europe's wound-healing sorbion GmbH &
Co. KG ("sorbion") branded product line, including sorbion's sachet S wound
products that Carolon has been selling. Access to the distribution network,
customers and sales force provided by the Carolon agreement will be leveraged
to sell the sorbion products as well as the Company's hydrogel product line,
which is sold under the SilverSeal® and Hydress® brands. 

To read the entire press release, please go

Highlights For ALQA Distributorship:

• Alliqua becomes exclusive sales agent of sorbion-branded products in the

• Gains access to Carolon's established distribution relationships with major
wholesalers and healthcare facilities in the wound healing industry

• Obtains contract opportunities with experienced wound-sales force, thereby
adding strength and reach to Alliqua's existing team

• Sales force may now also represent and sell Alliqua's 510(k) FDA-approved
hydrogel products for wound care (marketed under the SilverSeal and Hydress
brands) through the expanded distribution channels

• Alliqua significantly enhances potential sales footprint for future product
line acquisitions and partnerships

Pacific Biosciences of California Inc. (NASDAQ: PACB), provider of the PacBio
® RS II DNA Sequencing System, announced that it has entered into an agreement
with Roche Diagnostics to develop diagnostic products, including sequencing
systems and consumables, based on Pacific Biosciences' Single Molecule,
Real-Time (SMRT ®) technology. Pacific Biosciences will develop and
manufacture certain products intended for clinical use, which it will sell
exclusively to Roche. Roche obtained worldwide rights to exclusively
distribute these products in the field of human in vitro diagnostics. Pacific
Biosciences will continue to market its current and future products for all
fields outside of human in vitro diagnostics, including research, plant,
animal, and applied markets.

Oncothyreon Inc. (NASDAQ: ONTY) announced that Merck Serono, the
biopharmaceutical division of Merck KGaA, has decided to continue clinical
development of the investigational MUC1 antigen-specific cancer immunotherapy
tecemotide (also known as L-BLP25 and formerly known as Stimuvax®). Merck
Serono, which is developing tecemotide under a license agreement with
Oncothyreon, will conduct a new Phase 3 trial called START2 for patients with
unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) announced on Tuesday that Ron
Bentsur, the Company's Chief Executive Officer, will be presenting at
BioCentury's NewsMakers in the Biotech Industry Conference at 3:00 pm EDT on
Friday, September 27, 2013, in New York City. A live audio webcast of Mr.
Bentsur's presentation will be accessible from the Investor Information page
of the Company's Website at An archived version of
this webcast will be available following the conclusion of the live

Organovo Holdings, Inc. (NYSE: ONVO) develops three-dimensional (3D)
bioprinting technology for creating functional human tissues on demand for
research and medical applications. The company's 3D NovoGen bioprinting
technology works across various tissue and cell types, and allows for the
placement of cells in desired pattern. It offers NovoGen MMX Bioprinter, a
commercial hardware and software bioprinter platform to create tissues for
bioprinting research and development. ONVO closed up 1.51% on Wednesday on
over 3Mil shares traded. is leading provider of third party publishing &news
dissemination services. If you would like more information regarding our news
coverage solutions, please visit for more
details. Get an edge on the market with ourPremium News Alerts that are
FREE for a limited time at Follow us on
Facebook: and
Twitter: Sign up for our FREE SMS News alerts
delivered directly to your mobile phone by texting the word PRESS to
545454.(SMS alerts are free, however data rates may apply, check your
wireless plan for details.)

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNMG is NOT affiliated in any manner
with any company mentioned herein. FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material. All readers are strongly urged to perform research and due
diligence on their own and consult a licensed financial professional before
considering any level of investing in stocks. The companies that are
discussed in this release may or may not have approved the statements made in
this release. FNMG is not liable for any investment decisions by its readers
or subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks.


This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email:
U.S. Phone: +1(954)345-0611

Press spacebar to pause and continue. Press esc to stop.